# Part 2: Evidence Evaluation and Management of Conflicts of Interest

by Laurie J. Morrison, Lana M. Gent, Eddy Lang, Mark E. Nunnally, Melissa J. Parker, Clifton W. Callaway, Vinay M. Nadkarni, Antonio R. Fernandez, John E. Billi, Jonathan R. Egan, Russell E. Griffin, Michael Shuster, and Mary Fran Hazinski

> Circulation Volume 132(18 suppl 2):S368-S382 November 3, 2015




### Applying Class of Recommendations and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care\*.

CL

LASS (STRENGTH) OF RECOMMENDATION		LEVEL (QUALITY) OF EVIDENCE‡		
SS I (STRONG) B	enefit >>> Risk	LEVEL A		
Suggested phrases for writing recommendations: <ul> <li>Is recommended</li> <li>Is indicated/useful/effective/beneficial</li> <li>Should be performed/administered/other</li> </ul>		<ul> <li>High-quality evidence‡ from more than 1 RCTs</li> <li>Meta-analyses of high-quality RCTs</li> <li>One or more RCTs corroborated by high-quality registry studies</li> </ul>		
Comparative-Effectiveness Phrases†: • Treatment/strategy A is recommended/indiv	poted in	LEVEL B-R	(Randomized)	
<ul> <li>reatment strategy as recommended infinite</li> <li>preference to treatment B</li> <li>Treatment A should be chosen over treatment</li> </ul>		<ul> <li>Moderate-quality evidence‡ from :</li> <li>Meta-analyses of moderate-quality</li> </ul>		
S IIa (MODERATE)	Benefit >> Risk	LEVEL B-NR	(Nonrandomized)	
uggested phrases for writing recommendations: Is reasonable Can be useful/effective/beneficial Comparative-Effectiveness Phrases†: • Treatment/strategy A is probably recommend	led/indicated in	<ul> <li>Moderate-quality evidence‡ from : well-executed nonrandomized studies, or registry studies</li> <li>Meta-analyses of such studies</li> </ul>		
preference to treatment B		LEVEL C-LD	(Limited Data)	
It is reasonable to choose treatment A over treatment B		<ul> <li>Randomized or nonrandomized ob studies with limitations of design of</li> </ul>		
It (WEAK) Benefit ≥ Risk uggested phrases for writing recommendations: May/might be reasonable		<ul> <li>Meta-analyses of such studies</li> <li>Device of such studies</li> </ul>	aa in human auhiaata	
		Physiological or mechanistic studie	es in numan subjects	
May/might be considered		LEVEL C-EO	(Expert Opinion)	
<ul> <li>Usefulness/effectiveness is unknown/unclear/uncertain or not well established</li> </ul>		Consensus of expert opinion based on clinical experience		
S III: No Benefit (MODERATE) ally, LOE A or B use only)	Benefit = Risk	COR and LOE are determined independently (any	COR may be paired with any LOE).	
Suggested phrases for writing recommendations: Is not recommended Is not indicated/useful/effective/beneficial Should not be performed/administered/other		A recommendation with LOE C does not imply that the recommendation is weak. Many important clinical questions addressed in guidelines do not lend themselves to clinical trials. Although RCTs are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.		
		* The outcome or result of the intervention should be specified (an improved clinical outcome or increased diagnostic accuracy or incremental prognostic information).		
S III: Harm (STRONG)	Risk > Benefit	† For comparative-effectiveness recommendations (COR I and IIa; LOE A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.		
uggested phrases for writing recommendations: Potentially harmful Causes harm		<ul> <li>the method of assessing quality is evolved.</li> <li>The method of assessing quality is evolved, including the application of standardized widely used, and preferably validated evidence grading tools; and for systematic revie the incorporation of an Evidence Review Committee.</li> </ul>		
<ul> <li>Associated with excess morbidity/mortality</li> <li>Should not be performed/administered/other</li> </ul>		COR indicates Class of Recommendation; EO, expert opinion; LD, limited data; LOE, Leve of Evidence; NR, nonrandomized; R, randomized; and RCT, randomized controlled trial.		




Structure of questions for evidence evaluation.






#### ILCOR 2015 Consensus on Science work flow for all systematic reviews.



Laurie J. Morrison et al. Circulation. 2015;132:S368-S382




ILCOR process for prioritizing PICO questions for systematic reviews.



Laurie J. Morrison et al. Circulation. 2015;132:S368-S382



Comparison of the number of systematic review questions (PICO questions) addressed or deferred/not reviewed in 2015 versus 2010 reported by Part in the ILCOR International Consensus on CPR and ECC Science With Treatment Recommendations (CoSTR) publication.




## Number of ILCOR PICO Questions

Laurie J. Morrison et al. Circulation. 2015;132:S368-S382




Class of Recommendation comparison between 2010 Guidelines and 2015 Guidelines Update.



### Distribution of Recommendations by Class in 2010 and 2015

Laurie J. Morrison et al. Circulation. 2015;132:S368-S382






## Distribution of Levels of Evidence in 2010 and 2015 Recommendations




Developing an AHA ECC recommendation that is informed by a GRADE strong recommendation in favor of a therapy or diagnostic or prognostic test.



Laurie J. Morrison et al. Circulation. 2015;132:S368-S382




### Developing an AHA ECC recommendation that is informed by a GRADE weak recommendation in favor of a therapy or diagnostic or prognostic test.



Laurie J. Morrison et al. Circulation. 2015;132:S368-S382




Developing an AHA ECC recommendation that is informed by a GRADE strong or weak recommendation against a therapy or diagnostic or prognostic test.





The Utstein Formula of Survival, emphasizing the 3 components essential to improve survival.



Laurie J. Morrison et al. Circulation. 2015;132:S368-S382

